Emerging drugs for eosinophilic esophagitis (Q38128368)

29 August 2017

Emerging drugs for eosinophilic esophagitis. (English)

1 reference

29 August 2017

Emily Kern

1

1 reference

PubMed ID

23937314

29 August 2017

Ikuo Hirano

series ordinal

2

1 reference

PubMed ID

23937314

29 August 2017

language of work or name

English

0 references

publication date

13 August 2013

1 reference

Expert Opinion on Emerging Drugs

29 August 2017

1 reference

29 August 2017

18

1 reference

29 August 2017

353-364

1 reference

29 August 2017

3

1 reference

ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE).

29 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Eosinophilic esophagitis: updated consensus recommendations for children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Qualitative assessment of patient-reported outcomes in adults with eosinophilic esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Cost-effectiveness model of endoscopic biopsy for eosinophilic esophagitis in patients with refractory GERD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Cross-sector sponsorship of research in eosinophilic esophagitis: a collaborative model for rational drug development in rare diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Therapeutic concepts in adult and paediatric eosinophilic oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Eosinophilic esophagitis: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Diet therapy for eosinophilic esophagitis: when, why and how.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Successful treatment of eosinophilic esophagitis with ciclesonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Topical inhaled ciclesonide for treatment of eosinophilic esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Active eosinophilic esophagitis is associated with impaired elimination of budesonide by cytochrome P450 3A enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Understanding eosinophilic esophagitis: the cellular and molecular mechanisms of an emerging disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

T cell co-stimulatory molecules: a co-conspirator in the pathogenesis of eosinophilic esophagitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Eosinophilic esophagitis: rapidly advancing insights.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Interleukin 13 and its role in gut defence and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Tissue remodeling in eosinophilic esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Genetic dissection of eosinophilic esophagitis provides insight into disease pathogenesis and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Biology and treatment of eosinophilic esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Eosinophilic oesophagitis: a novel treatment using Montelukast

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Observations on use of montelukast in pediatric eosinophilic esophagitis: insights for the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Angiotensin II blockade and aortic-root dilation in Marfan's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Fluticasone and food allergen elimination reverse sub-epithelial fibrosis in children with eosinophilic esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Esophageal diameter is decreased in some patients with eosinophilic esophagitis and might increase with topical corticosteroid therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Dissociation between symptoms and histological severity in pediatric eosinophilic esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Eosinophilic gastrointestinal diseases--clinically diverse and histopathologically confounding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Glucocorticoid-regulated genes in eosinophilic esophagitis: a role for FKBP51.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Resolution of remodeling in eosinophilic esophagitis correlates with epithelial response to topical corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Esophageal dilation in eosinophilic esophagitis: effectiveness, safety, and impact on the underlying inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

Escalating incidence of eosinophilic esophagitis: A 20-year prospective, population-based study in Olten County, Switzerland

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.829039

10.1517/14728214.2013.829039

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

23937314